Group 1 - The core viewpoint of the article is that Borui Biotech is preparing for an IPO on the Hong Kong Stock Exchange with an estimated valuation of approximately 13.5 billion [1] - Borui Biotech is a comprehensive integrated biopharmaceutical company in China, with its history tracing back to the biopharmaceutical division of Haizheng Pharmaceutical [1] - The company underwent a restructuring into a limited liability company in 2019 and plans to convert into a joint-stock company by 2025, with major shareholders including PAG (44.62%) and Haizheng Pharmaceutical (39.62%) [1] Group 2 - Borui Biotech has eight commercialized products and is expected to generate significant revenue from 2023 to September 2025 [1] - In October 2024, Borui Biotech signed a promotion service agreement with Youshibi, obtaining exclusive CSO authorization [1] - In January 2025, the company entered into a licensing and collaboration agreement with Shandon Pharmaceuticals to develop and commercialize BR2251 [1]
博锐生物拟在港交所上市，华泰国际和摩根大通担任联席保荐
Cai Jing Wang·2026-01-07 06:42